TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30448451
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (IGlar) U100 + insulin aspart (IAsp) once-daily (OD)
Study: 26896686
Drug: Cervarix™ HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervarix™ HPV vaccine
Study: 26896686
Drug: Gardasil™ HPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil™ HPV vaccine
Study: 20308489
Drug: Body Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Weight (BW) group with contrast dose of 360 mg I/kg BW
Study: 20308489
Drug: Body Surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Surface Area (BSA) group with contrast dose of 12,753 mg I/m(2) BSA
Study: 17369673
Drug: Surgery as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery as the dominant form of therapy
Study: 12395978
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg alone
Study: 12395978
Drug: Concomitant nateglinide
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant nateglinide 120 mg and diclofenac 75 mg
Study: 10048900
Drug: Low-dose nandrolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nandrolone decanoate (65 mg/week)
Study: 10048900
Drug: High-dose nandrolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nandrolone decanoate (200 mg/week)
Study: 10048900
Drug: Nandrolone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nandrolone treatment (both doses)
Study: 10048900
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate therapy (12-week open-label follow-up)
Study: 31599827
Drug: Self-discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-discontinuation
Study: 31599827
Drug: Office discontinuation
Normalized name: Entex HC Discontinued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office discontinuation
Study: 27338456
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 400 μg (two times/daily) for three months
Study: 22493925
Drug: Tuina treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuina treatment (local manipulations on breasts combined with acupoint manipulations)
Study: 18202422
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (100 mg/m²) with carboplatin (AUC = 6 mg/mL x min)
Study: 18202422
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen of paclitaxel (225 mg/m²) and carboplatin (AUC = 6) every 3 weeks
Study: 24456145
Drug: IOP-lowering therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOP-lowering therapy
Study: 15700191
Drug: No IOP-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IOP-lowering therapy
Study: 10626564
Drug: Oestrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen therapy initiated at 12 years of age
Study: 10626564
Drug: Oestrogen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen therapy initiated at 15 years of age
Study: 8529507
Drug: Glimepiride (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (in severe patients treated by large doses of glibenclamide)
Study: 1949925
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg i.v.
Study: 31026534
Drug: Levodopa therapy
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa therapy (ON-medication condition)
Study: 31026534
Drug: Levodopa therapy
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa therapy (OFF-medication condition)
Study: 26220734
Drug: Soluble tumor
Normalized name: SOLUBLE TUMOR NECROSIS FACTOR (1-METHIONINE,31-CYSTEINE,69-VALINE,87-HISTIDINE,101-ALANINE,145-ARGININE) (HUMAN CONSTRUCT XPRO1595), 31-THIOETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOPROPYL)AMINO)PROPYL)-.OMEGA.-METHOXYPOLY(OXY-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble tumor necrosis factor receptor‐2 (sTNFRII)
Study: 19671303
Drug: TENS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS treatment at acupoints ST36 (Zusanli) and PC6 (Neiguan) twice a day for 2 weeks
Study: 15777070
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 1200 IU daily
Study: 9581727
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g three times daily)
Study: 7994817
Drug: Renin inhibitor
Normalized name: Renin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin inhibitor remikiren
Study: 7994817
Drug: Converting enzyme
Normalized name: Prohormone converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting enzyme inhibitor enalaprilat
Study: 7994817
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of remikiren and enalaprilat
Study: 2662790
Drug: Repeat trial
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat trial of conservative therapy
Study: 30875343
Drug: ECT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECT plus 5 mg/d donepezil
Study: 29169373
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of hypertensive medication
Study: 29169373
Drug: Evening dosing
Normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening dosing of hypertensive medication
Study: 26427805
Drug: Accelerated fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated fractionation (AF) - 1.1Gy+2Gy per day, 5 days/week for 4.5 weeks, total dose 68Gy
Study: 26427805
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (CF) - 2Gy per day, 5 days/week for 7 weeks, total dose 68Gy
Study: 18422441
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g valacyclovir TID for 7 days
Study: 18422441
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g valacyclovir TID for 7 days
Study: 18422441
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg acyclovir 5 times per day for 7 days (previous study)
Study: 12846625
Drug: Neuromuscular-blocking agent
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular-blocking agent (NMB) with tracheal tube ventilation
Study: 7798068
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg
Study: 26418414
Drug: CAPSULE (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPSULE (50 mg)
Study: 26418414
Drug: TABLET (diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: TABLET (diclofenac sodium enteric-coated tablet)
Study: 24831596
Drug: Traditional endovascular
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional endovascular coiling therapy
Study: 22221615
Drug: PAB-F (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAB-F (pantoprazole 40mg-bid, amoxicillin 1g-bid, bismuth subcitrate 240mg-bid for 2 weeks, furazolidone 200mg-bid for the first week)
Study: 22221615
Drug: PA-CT (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA-CT (pantoprazole 40mg-bid for 10 days, amoxicillin 1g-bid for the first 5 days, clarithromycin 500mg-bid plus tinidazole 500mg-bid for the second 5 days)
Study: 20460065
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (RSWT)
Study: 9358111
Drug: Topical oat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oat colloidal grain suspension (0.007% and 0.7%)
Study: 9358111
Drug: Topical rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rice colloidal grain suspension (0.007% and 0.7%)
Study: 8261678
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol (2 micrograms postdialysis three times per week)
Study: 8261678
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol (2 micrograms postdialysis three times per week)
Study: 8261678
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous and oral calcitriol
Study: 29967954
Drug: Prasugrel (20/3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (20/3.75 mg, loading/maintenance dose) with aspirin (100 mg)
Study: 29967954
Drug: Clopidogrel (300/75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300/75 mg) with aspirin (100 mg)
Study: 27562352
Drug: Tea catechin
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tea catechin beverage (570 mg)
Study: 20182703
Drug: tamsulosin, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin, 0.4 mg/day for 4 weeks
Study: 12357146
Drug: Goal-directed intraoperative
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed intraoperative fluid administration (protocol group)
Study: 16351767
Drug: Olive oil-based
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil-based intravenous lipid emulsion (ILE)
Study: 1912556
Drug: Self-administered IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered IFN alpha‐2b, 3 million units subcutaneously thrice weekly for 1 year (n = 10)
Study: 1912556
Drug: Self-administered IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered IFN alpha‐2b, 3 million units subcutaneously thrice weekly for 6 months (n = 6 after initial no-treatment)
Study: 1912556
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) (n = 8)
Study: 1912556
Drug: IFN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN treatment for 1 year
Study: 1912556
Drug: IFN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN treatment for 6 months
Study: 31050709
Drug: AKT-inhibitors in
Approvals — FDA: no, EMA: no, PMDA: no
Description: AKT-inhibitors in combination with first-line chemotherapy
Study: 28425253
Drug: B2-G haplotype
Approvals — FDA: no, EMA: no, PMDA: no
Description: B2-G haplotype
Study: 26019464
Drug: Bio‐Three tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio‐Three tablets (9 tablets/day) containing 2 mg of lactomin, 10 mg of Clostridium butyricum TO‐A, and 10 mg of Bacillus mesentericus TO‐A
Study: 26019464
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (9 tablets/day)
Study: 19430040
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antioxidant Phenovin and immunomodulator Una de gato
Study: 15538131
Drug: S-adenosyl-L-methionine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (800 to 1600 mg)
Study: 9269759
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg) administered intravenously 2 hours before endotoxin challenge
Study: 9269759
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg) administered subcutaneously 24 hours before endotoxin challenge
Study: 8329254
Drug: Buprenorphine 0.15
Normalized name: buprenorphine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.15 mg i.v. followed by buprenorphine 0.3 mg i.m. and then buprenorphine 0.4 mg sublingual
Study: 8329254
Drug: Papaveretum 10
Normalized name: papaveretum 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum 10 mg i.v. followed by papaveretum 20 mg i.m. and then buprenorphine 0.4 mg sublingual
Study: 8329254
Drug: Buprenorphine 0.15
Normalized name: buprenorphine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.15 mg i.v. followed by papaveretum 20 mg i.m. and then buprenorphine 0.4 mg sublingual
Study: 8329254
Drug: Papaveretum 10
Normalized name: papaveretum 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaveretum 10 mg i.v. followed by buprenorphine 0.3 mg i.m. and then buprenorphine 0.4 mg sublingual
Study: 2883393
Drug: Ty21a attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ty21a attenuated Salmonella typhi oral vaccine in an enteric‐coated formulation
Study: 2883393
Drug: Ty21a vaccine
Normalized name: Typhoid Vaccine Live Ty21a
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ty21a vaccine in gelatin capsules with sodium bicarbonate
Study: 26438518
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder supplementation with 300 mg calcium per day (Group A)
Study: 26438518
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder supplementation with 600 mg calcium per day (Group B)
Study: 26438518
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder supplementation with 900 mg calcium per day (Group C)
Study: 25251201
Drug: Injectable, extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable, extended-release naltrexone
Study: 23063084
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g IV (GrAP)
Study: 23063084
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (GrAPn)
Study: 15530588
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of at least 5 g
Study: 12180276
Drug: Topiramate (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (50-300 mg/day)
Study: 12180276
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (100-400 mg/day)
Study: 9666536
Drug: Targeted low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Targeted low-dose warfarin (INR 1.5-2.0)
Study: 8582151
Drug: Active antiplatelet
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antiplatelet regimens (including aspirin)
Study: 31550951
Drug: Single lightwand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single lightwand (Group L)
Study: 21787508
Drug: Taper 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper 0.04
Study: 21787508
Drug: Taper 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper 0.06
Study: 21787508
Drug: Taper 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper 0.08
Study: 9299674
Drug: Decision-making strategy
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decision-making strategy A (combination of disease indices and serum concentrations of orosomucoid)
Study: 8117512
Drug: Subtrochanteric resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtrochanteric resection and double plate compound osteosynthesis (DPCO)
Study: 31101513
Drug: Co-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-treatment with buspirone and AAPDs
Study: 31101513
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with AAPDs
Study: 19187641
Drug: Rapid fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid fluid expansion (Group I, n = 36) at a rate of 10-15 ml x kg(‐1) x h(‐1)
Study: 19187641
Drug: Controlled fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled fluid expansion (Group II, n = 40) at a rate of 5-10 ml x kg(‐1) x h(‐1)
Study: 17202428
Drug: Real-time feedback
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time feedback display of movement; adaptation to three different rotations of feedback display; sequential adaptation process.
Study: 11573597
Drug: Erythromycin 1
Normalized name: erythromycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 1 mg kg(‐1)
Study: 11573597
Drug: Metoclopramide 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 0.15 mg kg(‐1)
Study: 24002121
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times daily for 9 months
Study: 24002121
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg daily for 9 months
Study: 8622077
Drug: Radioimmunoguided surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioimmunoguided surgery (RIGS) using iodine 125‐labeled monoclonal antibodies (MAbs) B72.3 (anti‐TAG72)
Study: 8622077
Drug: Radioimmunoguided surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioimmunoguided surgery (RIGS) using iodine 125‐labeled monoclonal antibodies (MAbs) FO23C5 (anti‐carcinoembryonic antigen [CEA])
Study: 3914702
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/d
Study: 27087092
Drug: TEST 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEST 500 mg
Study: 27087092
Drug: REF® 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: REF® 500 mg
Study: 22318492
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral desensitization protocol enabled with omalizumab (anti-IgE monoclonal antibodies)
Study: 19514438
Drug: PEA with
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEA with intramuscular ketorolac
Study: 19514438
Drug: PEA with
Normalized name: Pea
DrugBank: Pea (DB10551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEA with intramuscular ketorolac and intravenous paracetamol
Study: 11410120
Drug: Oral combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combined hormone replacement therapy (HRT)
Study: 18261392
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy (Acenocoumarol)
Study: 12829890
Drug: Tac and
Normalized name: Nystatin and Triamcinolone Acetonide Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tac and steroids (control)
Study: 12829890
Drug: TacSRL0.5 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TacSRL0.5 (0.5 mg SRL)
Study: 12829890
Drug: TacSRL1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TacSRL1 (1 mg SRL)
Study: 12829890
Drug: TacSRL2 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TacSRL2 (2 mg SRL)
Study: 6542402
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg single dose)
Study: 6542402
Drug: Integrated chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated chemotherapy, sanitation improvement, and health education
Study: 6542402
Drug: Control (only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (only chemotherapy)
Study: 31914451
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Clopidogrel (ASP-CLO)
Study: 22900932
Drug: Screening intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Screening intervention (fasting plasma glucose measurement and referral to GP if FPG ≥ 6.1 mmol/L)
Study: 18937623
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac formulations (sodium lotion, lecithin or epolamine gel, patch or plaster)
Study: 18937623
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac formulations
Study: 15769238
Drug: Presentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation of performance information with small numbers (e.g., absence rates of 2% vs. 5%)
Study: 15769238
Drug: Presentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation of performance information with large numbers (e.g., attendance rates of 98% vs. 95%)
Study: 10094298
Drug: Multi-sensory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-sensory stimulation (auditory, tactile, visual, and vestibular intervention) for 15 minutes, twice a day, five days a week, for four weeks during hospitalization
Study: 7538547
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with zidovudine and L‐697,661
Study: 7538547
Drug: L‐697,661 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐697,661 alone
Study: 6631566
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g orally once a day, five times a week for 20 weeks)
Study: 6631566
Drug: Zinc (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (60 mg as zinc gluconate once a day, five times a week for eight weeks)